Amprion

Amprion operates in the specialized neurodegenerative diagnostics segment, focusing on biological detection of misfolded proteins rather than relying solely on clinical symptoms or imaging. Its core differentiation is the use of seed amplification assay technology, including SAAmplify-αSYN, SAAmplify-αSYN Plus, SYNTap, and related αSynSAA methods, to identify disease-associated alpha-synuclein in cerebrospinal fluid. The company also combines laboratory services with research and biopharma collaborations, extending its role beyond a single diagnostic product. Its CAP-accredited and CLIA-certified laboratory infrastructure, FDA Breakthrough Device Designation, and reported permits in multiple U.S. states create operational and regulatory advantages in a technically demanding market. Partnerships with Modality.AI, Macquarie University, MLM Medical Labs, academic groups, foundations, and pharmaceutical organizations broaden potential clinical and research applications. Amprion’s $17.06 million in recorded funding and 2026 product expansion indicate a focused, clinically oriented position rather than a broad diagnostic platform strategy.

Amprion’s growth trajectory shows a shift from technology development toward broader clinical deployment and international research access. Founded in 2007, the company has built a neurodegenerative disease diagnostics platform around seed amplification assays and alpha-synuclein biomarkers. The 2022 venture round of $10.96 million provided the largest disclosed financing event, followed by a $6 million Series B led by Formation Venture Engineering on Sep 25, 2024 and a $100,000 ALS Network grant on Sep 12, 2024. Product activity became more visible in 2026: a Macquarie University collaboration announced on Apr 3, 2026 supported deployment of SAAmplify-αSYN in Australia, while the Modality.AI collaboration on Jul 9, 2026 added digital assessment capabilities. The launch of SAAmplify-αSYN Plus on Sep 15, 2026 marked a move toward more differentiated disease characterization, specifically separating multiple system atrophy from Parkinson’s disease. The MLM Medical Labs licensing collaboration further supports European trial capacity.